FDA Approves New Drug to Prevent RSV in Babies and Toddlers
Today, the U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants...
A new immunization hinted at an end to bad RSV seasons. But an ... - CNN
Dec 5, 2023 · On November 16, the CDC and FDA announced that they had expedited the availability of 77,000 additional 100-mg doses of Beyfortus and that these would go to government and private programs.
Beyfortus approved in the US for the prevention of RSV lower ...
Jul 17, 2023 · AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second...
There’s a new shot to protect newborns from a serious ... - CNN
Oct 5, 2023 · The new shot, which goes by the brand name Beyfortus, slashed infants’ risk of being hospitalized for RSV by 80% in clinical trials. It promised to be a game-changer for the youngest patients.
Press Room - Sanofi US News
Updated as of October 26, 2023. There has been unprecedented demand for Beyfortus™ (nirsevimab-alip). For the first time in history, health care providers are able to help protect an extraordinary number of infants against respiratory syncytial virus (RSV) disease.
Sanofi shipping BEYFORTUS® in US to help protect ... - news…
Sep 16, 2024 · BEYFORTUS is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Thomas Grenier.
More doses of new RSV immunization for babies are on the way ... - CNN
Dec 14, 2023 · CNN — More hard-to-find doses of Beyfortus, the new immunization against respiratory syncytial virus (RSV) for infants, will be available in January, the White House says. The announcement comes...
FDA approves nirsevimab to prevent RSV in infants
Jul 17, 2023 · The monoclonal antibody nirsevimab (brand name Beyfortus) was approved as a single injection for infants born during or entering their first RSV season and young children up to 24 months who remain at risk of severe disease in their second RSV season.
Press Room - Sanofi US News
Jul 17, 2023 · Beyfortus™ is the first monoclonal antibody approved to protect all infants through their first RSV season. Across all clinical endpoints, a single dose of Beyfortus delivered high, consistent and sustained efficacy and favorable safety against RSV disease.
Beyfortus® immunization to protect infants from RSV has begun
Oct 28, 2024 · Beyfortus ® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus ® is also indicated for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
- Some results have been removed